Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

Researchers used Mendelian randomization to uncover causal links between gut microbiota, blood metabolites, and short stature ...

Stimulation of epidermal keratinocytes by insulin-like growth factor I (IGF-I ... potential as antipsoriasis therapeutic agents. Figure 1: Reduction in IGF-I receptor mRNA in HaCaT cells following ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

Lonapegsomatropin demonstrated efficacy outcomes superior to daily somatropin in treatment of pediatric growth hormone deficiency.

Hormones and some compounds in milk can boost insulin resistance and androgen male hormone production in women with ...

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases ...